Kivizidiale

Timolol/Travoprost, the active ingredient in Kivizidiale, is a beta blocker/prostaglandin analog presented as eye drops for ocular use. It lowers intra‑ocular pressure and is prescribed for patients with primary open‑angle glaucoma or ocular hypertension. GNH USA supplies Kivizidiale as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Kivizidiale is used in the management of ocular conditions where reduction of intra‑ocular pressure is required. - Primary open‑angle glaucoma: lowers intra‑ocular pressure to slow optic nerve damage. - Ocular hypertension: reduces pressure to prevent progression to glaucoma. - Post‑operative ocular hypertension: helps control pressure spikes after eye surgery.

Kivizidiale may cause ocular and systemic reactions.

Common Side Effects: - Eye irritation or burning sensation. - Blurred vision shortly after instillation. - Conjunctival hyperemia (red eye). - Dry eye or foreign‑body sensation. - Transient headache. - Mild eyelid edema.

Serious or Rare Side Effects: - Severe allergic reaction with swelling or rash. - Worsening of glaucoma or sudden pressure increase. - Systemic bradycardia or hypotension. - Respiratory distress in asthmatic patients. - Chest pain or myocardial ischemia. - Ocular infection or corneal ulceration.

Before prescribing Kivizidiale, clinicians should consider patient‑specific factors and monitor for adverse events. - Cardiovascular assessment: evaluate for bradycardia or heart block. - Respiratory status: avoid in patients with severe asthma or COPD. - Pregnancy and lactation: use only if benefits outweigh risks. - Concomitant beta‑blocker therapy: monitor for additive systemic effects. - Contact lens wearers: remove lenses before instillation and wait before reinserting. - Store at room temperature: keep in original container, protect from moisture and direct light.

Kivizidiale can interact with other medicines that affect ocular pressure or systemic beta‑adrenergic activity.

Major Interactions (Avoid): - Systemic non‑selective beta‑blockers: may cause excessive bradycardia or hypotension. - Other ocular beta‑blocker drops: risk of additive ocular hypotensive effect. - Sympathomimetic agents (e.g., epinephrine eye drops): may reduce efficacy.

Moderate Interactions (Monitor Closely):\n- Carbonic anhydrase inhibitor eye drops: may enhance intra‑ocular pressure reduction. - Anticholinergic ophthalmic agents: monitor for pupil changes. - NSAID eye drops: watch for increased ocular irritation.